News

Data Curation and Entry in DIDB – April Summary

In April, we added 92 citations in DIDB, including 44 in vitro (with 22 articles published in Apr. 2022) and 48 in vivo articles (with 36 articles published in Apr. 2022).

Four recently approved NDAs/BLAs were also added with the following 3 NDAs: utetium Lu-177 vipivotide tetraxetan (PLUVICTO), mitapivat (PYRUKYND), pacritinib (VONJO), and the following BLA: nivolumab and relatlimab (OPDUALAG).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

DDI Marker Studies Knowledgebase updated

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated and is available in the DIDB Resource Center.

Note, that we have initiated the gradual expansion of the Knowledgebase with more transporter data beyond P-gp. Thus, in this version, you will find data for BCRP and OATP1B1/1B3. More transporter data will be added throughout the year.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – March Summary

In March, we added 104 citations in DIDB, including 37 in vitro (with 11 articles published in Mar. 2022) and 67 in vivo articles (with 19 articles published in Mar. 2022).

Four recently approved NDAs/BLAs were also added with the following 1 NDA: daridorexant (QUVIVIQ), and the following 3 BLAs: faricimab (VABYSMO), sutimlimab (ENJAYMO), tebentafusp (KIMMTRAK).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – February Summary

In February, we added 126 citations in DIDB, including 43 in vitro (with 21 articles published in Feb. 2022) and 83 in vivo articles (with 30 articles published in Feb. 2022).

One NDA approved in Jan.2022 was also added: abrocitinib (CIBINQO).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

New features! AUC and Cmax (90% CI) data, PGx-FDA label, and more

DIDB has been updated with the following new features:

  • AUC and Cmax GMRs (90% CI) are now systematically presented in the study results view (when available) and are used to calculate changes in exposure data
  • Links to PGx external resources have been added to pharmacogenetics queries to provide users with additional contextual information
  • New drug characteristic “PGx (FDA label)” highlights drugs with PGx-related recommendations in FDA label
  • Continuous expansion of compound PK parameters

Feel free to contact us if you experience any issues or if you have any questions or suggestions. Your feedback is always greatly valued!

New Name and Additional Data! for the CYP/P-gp Substrates and Perpetrators Lists

Our new “DDI Marker Studies Knowledgebase” (in Excel) is now available in the Resource Center and replaces the previous combined and individual lists of CYP/P-gp substrates and perpetrators.

The Knowledgebase represents a comprehensive list of compounds that are sensitive or moderate sensitive substrates (NEW), inhibitors, or inducers of CYP enzymes (weak-to-strong potency assigned) and the P-gp transporter.

You can generate an individual list of a specific CYP isoform or transporter as shown in the video (at the bottom of the page).

Additionally, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality, accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

The Knowledgebase will be updated quarterly.

Feel free to contact us if you experience any issues or if you have any questions or suggestions. Your feedback is always greatly valued!

UW Pharmacy’s Drug Interaction Database, built to promote medication safety, wins national innovation award

2022 marks 20 years of DIDB licensing and the selection by the ASCPT of Dr. René Levy and Dr. Isabelle Ragueneau-Majlessi to receive the 2022 Gary Neil Prize for Innovation in Drug Development.

Read the story here: https://www.washington.edu/news/2022/01/13/uw-pharmacys-drug-interaction-database-built-to-promote-medication-safety-wins-national-innovation-award/

Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions

Abstract

Food effect (FE) and gastric pH-dependent drug-drug interactions (DDIs) are both absorption-related. Here, we evaluated if Biopharmaceutics Classification System (BCS) classes may be correlated with FE or pH-dependent DDIs. Trends in FE data were investigated for 170 drugs with clinical FE studies from the literature and new drugs approved from 2013 to 2019 by US Food and Drug Administration. A subset of 38 drugs was also evaluated to determine whether FE results can inform the need for a gastric pH-dependent DDI study. The results of FE studies were defined as no effect (AUC ratio 0.80-1.25), increased exposure (AUC ratio ≥1.25), or decreased exposure (AUC ratio ≤0.8). Drugs with significantly increased exposure FE (AUC ratio ≥2.0; N=14) were BCS Class 2 or 4, while drugs with significantly decreased exposure FE (AUC ratio ≤0.5; N=2) were BCS Class 1/3 or 3. The lack of FE was aligned with the lack of a pH-dependent DDI for all 7 BCS Class 1 or 3 drugs as expected. For the 13 BCS Class 2 or 4 weak base drugs with an increased exposure FE, 6 had a pH-dependent DDI (AUC ratio ≤0.8). Among the 16 BCS Class 2 or 4 weak base drugs with no FE, 6 had a pH-dependent DDI (AUC ratio ≤0.8). FE appears to have limited correlation with BCS classes except for BCS Class 1 drugs, confirming that multiple physiological mechanisms can impact FE. Lack of FE does not indicate absence of pH-dependent DDI for BCS Class 2 or 4 drugs.

Evaluating the feasibility of performing pharmacogenetic guided-medication therapy management in a retirement community: A prospective, single arm study

J Am Coll Clin Pharm. 2021;1-11
  • doi: 10.1002/jac5.1570
  • Semantic Scholar
  • Abstract

    New drug application reviews contain critical drug interaction study results with newly approved drugs tested both as victims and as perpetrators of drug-drug interactions (DDIs). Pharmacokinetic-based DDI data for drugs approved by the US Food and Drug Administration in 2013–2017 (N = 137) were analyzed using the University of Washington Drug Interaction Database. For the largest metabolism- and transporter-based drug interactions, defined as a change in exposure ≥ 5-fold in victim drugs, the mechanisms and clinical relevance were characterized. Consistent with the major role of CYP3A in drug disposition, CYP3A inhibition and induction explained a majority of the observed interactions (new drugs as victims or as perpetrators). However, transporter-mediated interactions were also prevalent, with OATP1B1/1B3 playing a significant role. As victims, 17 and 4 new molecular entities (NMEs) were identified to be sensitive substrates of enzymes and transporters, respectively. When considered as perpetrators, three drugs showed strong inhibition of CYP3A, one was a strong CYP3A inducer, and two showed strong inhibition of transporters (OATP1B1/1B3 and/or BCRP). All DDIs with AUC changes ≥ 5-fold had labeling recommendations in their respective drug labels, contraindicating or limiting the coadministration with known substrates or perpetrators of the enzyme/transporter involved. The majority of sensitive substrates or strong inhibitors were oncology and antiviral treatments, suggesting a significant risk of DDIs in these patient populations for whom therapeutic management is already complex due to poly-therapy. Pharmacogenetic studies and physiologically based pharmacokinetic models were commonly used to assess the drug interaction potential in specific populations and clinical scenarios. Finally, absorption-based DDIs were evaluated in approximately 30% of drug applications, and 14 NMEs had label recommendations based on the results.

    New features! and improvement of existing queries

    DIDB has been updated with the following new features:

    • Citations recently published” and “NDA/BLAs recently enters” can retrieve citations and NDA/BLAs containing PGx data only
    • The above result pages show if the citation or NDA/BLA contains in vitroin vivo, or PGx content
    • All the “In Vitro Parameter Queries” take multiple compounds
    • All query results now 
      • use the therapeutic class format of presenting two levels, e.g., “Antiemetics ⟶ Neurokinin-1 Receptor Antagonist”
      • both levels of the therapeutic class are links directed to the therapeutic class DDI risk assessment
      • drug names are now links if there is any DDI summary/QT summary/PK profile in their monographs

    Feel free to contact us if you experience any issues or if you have any questions or suggestions. Your feedback is always greatly valued!